Needham & Company LLC restated their buy rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research note released on Sunday. Needham & Company LLC currently has a $65.00 price target on the stock.

A number of other brokerages also recently commented on AERI. Canaccord Genuity set a $56.00 price objective on Aerie Pharmaceuticals and gave the company a buy rating in a research report on Monday, May 22nd. HC Wainwright reiterated a buy rating and set a $69.00 price objective on shares of Aerie Pharmaceuticals in a research report on Thursday, May 25th. Cantor Fitzgerald set a $56.00 price objective on Aerie Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, May 24th. Aegis increased their price objective on Aerie Pharmaceuticals from $63.00 to $70.00 and gave the company a buy rating in a research report on Thursday, May 25th. Finally, Cowen and Company set a $100.00 price objective on Aerie Pharmaceuticals and gave the company a buy rating in a research report on Friday, May 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $66.36.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at 58.60 on Friday. The stock’s market cap is $2.13 billion. Aerie Pharmaceuticals has a 52-week low of $32.05 and a 52-week high of $61.30. The firm’s 50-day moving average price is $54.83 and its 200 day moving average price is $50.04.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. Equities analysts predict that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/20/aerie-pharmaceuticals-aeri-buy-rating-reiterated-at-needham-company-llc.html.

Large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its stake in Aerie Pharmaceuticals by 28.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock valued at $10,115,000 after purchasing an additional 49,473 shares during the period. BlackRock Inc. raised its stake in Aerie Pharmaceuticals by 113,376.8% during the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after purchasing an additional 2,598,596 shares during the period. Boulegeris Investments Inc. raised its stake in Aerie Pharmaceuticals by 5.2% during the 2nd quarter. Boulegeris Investments Inc. now owns 79,525 shares of the company’s stock valued at $4,179,000 after purchasing an additional 3,900 shares during the period. Parametric Portfolio Associates LLC raised its stake in Aerie Pharmaceuticals by 5.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock valued at $3,102,000 after purchasing an additional 3,739 shares during the period. Finally, AXA acquired a new stake in Aerie Pharmaceuticals during the 2nd quarter valued at $10,961,000. 94.64% of the stock is currently owned by institutional investors.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.